Pro-Dex, Inc. (NASDAQ:PDEX) Shares Acquired by Fmr LLC

Fmr LLC grew its stake in Pro-Dex, Inc. (NASDAQ:PDEX) by 34.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,973 shares of the medical instruments supplier’s stock after purchasing an additional 1,028 shares during the quarter. Fmr LLC’s holdings in Pro-Dex were worth $119,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after acquiring an additional 900 shares during the last quarter. Bard Associates Inc. boosted its position in shares of Pro-Dex by 17.6% during the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Pro-Dex by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares in the last quarter. Institutional investors and hedge funds own 15.28% of the company’s stock.

Insider Activity at Pro-Dex

In other Pro-Dex news, CFO Alisha Charlton sold 1,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $40.02, for a total transaction of $40,020.00. Following the transaction, the chief financial officer now directly owns 15,339 shares in the company, valued at $613,866.78. This trade represents a 6.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 47.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PDEX shares. Ascendiant Capital Markets lifted their price target on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th.

Pro-Dex Stock Up 5.2 %

PDEX opened at $48.74 on Monday. The company has a market capitalization of $158.84 million, a PE ratio of 31.65 and a beta of 0.56. The business has a 50-day moving average of $42.12 and a 200-day moving average of $29.01. Pro-Dex, Inc. has a fifty-two week low of $16.18 and a fifty-two week high of $54.84. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94.

Pro-Dex Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.